RA101495-01.202: A multicenter, Open-Label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Ra Pharmaceuticals, Inc
Start Date
June 14, 2017
End Date
August 29, 2018
Administered By
Duke Cancer Institute
Awarded By
Ra Pharmaceuticals, Inc
Start Date
June 14, 2017
End Date
August 29, 2018